{"product_id":"ildong-swot-analysis","title":"Ildong Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals combines strong domestic market presence and a growing biosimilars pipeline with strategic R\u0026amp;D partnerships, yet faces margin pressure from generics competition and regulatory risks; its aging product portfolio and reliance on Korea weigh on scalability. Discover the complete picture behind the company’s market position with our full SWOT analysis—actionable, research-backed, and ready for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant OTC Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong holds a dominant share in South Korea’s OTC market, led by Aronaamin vitamin with estimated annual sales of about KRW 120 billion in 2024, giving steady cash flow and  strong repeat purchase rates.\u003c\/p\u003e\n\u003cp\u003eHigh brand recognition drives loyalty—Aronaamin’s penetration in adults 30–59 exceeds 40%—making it hard for rivals to displace.\u003c\/p\u003e\n\u003cp\u003eThe company leverages trust to roll out supplements; new launches in 2023–24 added ~8% to OTC revenue and expanded reach into younger demographics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global R\u0026amp;D Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals has proven skill in high-value global alliances, notably its 2023 co-development and licensing deal with Shionogi for the antiviral Xocova (molnupiravir variant), which included milestone payments of up to $60m and shared Phase II\/III financing. These partnerships cut Ildong’s clinical risk, speed drug timelines, and boosted export channels—international revenue rose 18% in 2024 on partnered products—strengthening its technical reputation and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Heritage and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith over 60 years in Korea’s healthcare market, Ildong Pharmaceuticals has built institutional trust—reflected in a 2024 domestic prescription share of ~3.8%—that eases entry into new therapeutic areas and boosts success in hospital procurement, where legacy relationships cut purchase lead times by months; this long-standing presence raises the barrier to entry for newer domestic rivals and supports steady OTC revenue (KRW 220 billion in 2024), reinforcing competitive resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Therapeutic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals holds a balanced product mix across gastroenterology, cardiovascular, and infectious-disease drugs, with chronic-therapy sales making up about 62% of prescription revenue in 2024, insulating it from single-market shocks.\u003c\/p\u003e\n\u003cp\u003eThis diversification supported stable top-line performance: 2024 revenue was KRW 542 billion, up 3.4% year-over-year, driven by steady demand for chronic-care prescriptions.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: chronic prescriptions ≈ KRW 336 billion (62% of 542b), keeping cashflows predictable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of 2024 prescription revenue from chronic therapies\u003c\/li\u003e\n\u003cli\u003e2024 revenue KRW 542 billion (+3.4% YoY)\u003c\/li\u003e\n\u003cli\u003eRevenue spread across gastro, cardio, infectious segments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals runs KGMP-certified plants and other global-standard facilities, enabling efficient production of proprietary drugs and premium generics.\u003c\/p\u003e\n\u003cp\u003eAutomated lines cut unit costs; management reported a 12% manufacturing cost reduction in 2024 and a 25% increase in output capacity for exports year-over-year.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eKGMP-certified facilities\u003c\/li\u003e\n\u003cli\u003e12% manufacturing cost reduction (2024)\u003c\/li\u003e\n\u003cli\u003e25% export capacity growth YoY\u003c\/li\u003e\n\u003cli\u003eScalable automated production\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong: Stable OTC core, 62% chronic revenue, +18% intl growth, -12% manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s strong OTC franchise (Aronaamin ≈ KRW 120b 2024) and 60+ year domestic trust drive repeat sales and ease hospital procurement; 2024 revenue KRW 542b (+3.4% YoY) with chronic prescriptions ≈ KRW 336b (62%). Global partnerships (eg, 2023 Shionogi deal, $60m milestones) lifted international sales +18% in 2024. KGMP plants cut manufacturing costs 12% in 2024 and raised export capacity 25% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 542b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronaamin sales\u003c\/td\u003e\n\u003ctd\u003eKRW 120b\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic prescriptions\u003c\/td\u003e\n\u003ctd\u003eKRW 336b (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue growth\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing cost cut\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport capacity growth\u003c\/td\u003e\n\u003ctd\u003e+25% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework analyzing Ildong Pharmaceuticals’s internal capabilities, market strengths, growth drivers, operational weaknesses, strategic opportunities in therapeutics and global expansion, and external threats such as regulatory changes, competition, and pricing pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Ildong Pharmaceuticals for quick strategic alignment, ideal for executives needing a high-level view to guide product, R\u0026amp;D, and market decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustained High R\u0026amp;D Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong has consistently spent high R\u0026amp;D: in 2024 R\u0026amp;D outlays were 18.7% of revenue (KRW 132.4bn), which compressed operating margin to 3.2% that year. While vital for pipeline growth, these investments caused net losses in 2019 and a near-breakeven 2022, and investors flag the burn rate when clinical timelines slip — e.g., phase III delays in 2023 pushed expected commercial revenue from 2025 to 2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Domestic Market Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 75% of Ildong Pharmaceuticals' FY2024 revenue came from South Korea, leaving the firm highly exposed to local GDP shifts and regulatory moves such as the 2023 Korean drug pricing reform that cut reimbursements by ~3–5% for some categories.\u003c\/p\u003e\n\u003cp\u003eThis domestic concentration constrains growth versus peers: multinational rivals report 40–60%+ non‑Korea sales, while Ildong’s international share remained ~25% in 2024.\u003c\/p\u003e\n\u003cp\u003eWithout direct sales networks in the US and EU, Ildong relies on third‑party distributors abroad, which reduced realized margins on exported products by an estimated 2–4 percentage points in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Debt-to-Equity Levels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of FY2024 Ildong Pharmaceuticals carried a debt-to-equity ratio near 1.8x, reflecting heavy borrowings to fund its KRW 240 billion R\u0026amp;D plan and 2023–24 plant upgrades; rising global rates and a potential 5–10% revenue dip could strain free cash flow and push interest coverage toward critical levels. Managing repayments while preserving R\u0026amp;D spend is a narrow path for management and could pressure the firm’s credit rating.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Licensed Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpildong pharmaceuticals relies materially on licensed prescription drugs from foreign partners with products accounting for about of sales in forcing royalty payouts that suppress net margins.\u003e\u003cpif key licenses lapse or aren renewed revenue volatility rises loss of a single major in-licensed product could cut prescription sales by based on figures.\u003e\u003cpdeveloping proprietary ip is essential: increasing internally developed assets would reduce royalties an estimated of revenue and improve long-term net margins.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensed products ≈28% of 2024 prescription sales\u003c\/li\u003e\n\u003cli\u003eRoyalties ≈5–7% of revenue in 2024\u003c\/li\u003e\n\u003cli\u003eLicense loss could cut ~15% of prescription sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdeveloping\u003e\u003c\/pif\u003e\u003c\/pildong\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Direct Global Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUnlike larger multinationals, Ildong Pharmaceuticals lacks an extensive proprietary global distribution network for its innovative drug candidates, limiting direct market reach and pricing control.\u003c\/p\u003e\n\u003cp\u003eAs of 2025 Ildong reports ~20% of revenue from licensing and partnership deals; out-licensing boosts cash but forfeits downstream margins that could add 30–50% to product lifetime value.\u003c\/p\u003e\n\u003cp\u003eBuilding independent international sales would likely require $200–400M and 3–5 years for infrastructure, regulatory, and commercial scale—capital and time Ildong has not fully committed to.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRelies on out-licensing; ~20% FY2025 revenue from deals\u003c\/li\u003e\n\u003cli\u003ePotential lost downstream margin: ~30–50%\u003c\/li\u003e\n\u003cli\u003eEstimated build cost: $200–400M; 3–5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D burn and domestic dependence squeeze margins; delays, 1.8x D\/E raise risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh R\u0026amp;D burn (18.7% rev, KRW132.4bn in 2024) compressed operating margin to 3.2% and caused past net losses; phase III delays pushed key launches from 2025 to 2027. FY2024 revenue 75% Korea exposure; licensing\/out‑licensing (~28% prescription sales; ~20% total 2025) and royalties (5–7% rev) limit margins. Debt\/equity ~1.8x risks cashflow under rate rises.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e18.7% rev (KRW132.4bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic sales\u003c\/td\u003e\n\u003ctd\u003e75% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed sales\u003c\/td\u003e\n\u003ctd\u003e28% prescription\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–7% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD\/E\u003c\/td\u003e\n\u003ctd\u003e~1.8x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version with in-depth insights on Ildong Pharmaceuticals’ strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752337027449,"sku":"ildong-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ildong-swot-analysis.png?v=1772239699","url":"https:\/\/matrixbcg.com\/products\/ildong-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}